VIENNA and SAN DIEGO, June 17, 2020 /PRNewswire/ -- Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowledge bases.

St. Louis, MO /PR Newswire/—Canopy Biosciences, a multi-omic CRO providing NanoString® nCounter® and RNA Seq services to both clinical and research customers, has partnered with Onramp BioInformatics™ to offer their ROSALIND™ interactive data analysis platform for Canopy’s gene expression services.  Launched earlier this year, Canopy has been providing this intuitive platform to customers that have run NanoString and RNA Seq projects.

I’m convinced, and I know most of you are too, that we will not get to a complete understanding of diseases and biology in general without looking behind a multi-omics lens. While NGS radically democratized access to genomics information with RNA-seq, for example, the complexity of other assays like ChIP-seq and the ensuing challenges in combining different types of data analyses have limited the wide scale adoption of multi-omics approaches.

NanoString and OnRamp BioInformatics Partner to Develop Cloud-Based Analysis Solutions for nCounter Data

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis tools, today announced a collaboration for the development of new analysis tools for data generated on NanoString’s nCounter® Analysis System. The new analysis functionality is built into ROSALIND™, OnRamp’s cloud-based analysis suite that facilitates data visualization, exploration and collaboration. The companies are releasing these new capabilities through early access and immediately offering it to COVID-19 researchers performing critical host response studies on the nCounter platform.

We’ve all been reminded across various social media feeds how Isaac Newton discovered calculus while “social distancing” during the Great Plague of London or how some of Shakespeare’s greatest works happened while in quarantine. Although the thought of being able to work from home was once a dream we wished for, as Adam Ruben, Ph.D. puts it, science-ing from home isn’t easy.

If juggling your altered home-life alongside the 9-5 work routine wasn’t challenging enough, it’s even more questionable how you can advance your research now that you have limited access to your laboratory, your data and your team.

As we all grapple with the new reality of lockdowns and work-from-home mandates, there’s now a new opportunity re-define what it truly means to do collaborative research and remote science anywhere in the world.

After conversations with thousands of Scientists, there is stunning lesson in their feedback that every Pharma and Biotech manager should internalize: Collaboration is more valuable than the underlying analysis pipelines.

No matter how great the pipeline, if Scientists can’t explore, interpret and consistently collaborate on a common version of the data then the value invested in the experiment is lost, or simply not realized.

Like dark data, the latent insights in these experiments remain trapped. Interestingly, Pharma and Biotech institutions with a deluge of clinical trial and research data are looking for collaboration tools for their Scientists, not the fundamental analysis pipelines. The implications for oncology research, immunology, drug discovery and disease research are significant.

• Something every Scientist should read: we walked through Collaboration Spaces on ROSALIND, highlighting how it's now possible to collaborate in real-time on genomic data (like Google Docs). Read the post here. 
• We've forever transformed Public Data exploration. Follow this link for more information.
• Learn more about the latest capabilities, supported species and levels of access in this post on empowering scientists.  

Schistosoma mansoni causes schistosomiasis, a disease of poverty that infects approximately 200 million people worldwide. Treatment of the disease relies on praziquantel (PZQ). With the expanding use of the drug, there is a fear over the development of resistance. It is, therefore, important to discover new drugs and drug targets.

I'm really happy to announce  another poster and research project utilizing ROSALIND, our analysis and collaboration platform for genomics.

Working with Public Data is important to nearly every Scientist in our community. Unfortunately, it's harder than it should be to work with these valuable datasets.  We all see and hear the news each week of exciting discoveries and breakthroughs in leading research, yet accessing and analyzing these Public Datasets, especially from RAW (SRA), requires determination, persistence and more coding skills than should be required of Scientists today.

OnRamp’s ROSALIND and Active Motif offer an improved ChIP-Seq data analysis experience for researchers with state-of-the-art dynamic track plots and advanced collaboration capabilities.